Predict your next investment

Corporation
HEALTHCARE | Biotechnology
zalicus.com

See what CB Insights has to offer

Founded Year

2000

Stage

Acq - P2P | Acquired

Total Raised

$76.4M

Valuation

$0000 

About Zalicus

Zalicus, formerly CombinatoRx, is a biopharmaceutical company focused on developing new medicines built from synergistic combinations of approved drugs, designed to attack disease on multiple fronts. CombinatoRx applies its proprietary combination drug discovery technology to identify new combination product candidates in a number of disease areas, including immunoinflammatory disease, oncology, metabolic disease, neurodegenerative disease, and infectious disease.

Zalicus Headquarter Location

245 First Street Third Floor

Cambridge, Massachusetts, 02142,

United States

617-301-7000

Latest Zalicus News

​Atlas startup Quartet adds $6M to funding for painkillers

Oct 7, 2015

Kevin Pojasek is president and acting CEO of Quartet Medicines, a new company developing… more Courtesy Atlas An early-stage biotech formed two years ago at Atlas Venture has brought in another $6 million in funding and named two new board members as it works to develop new kinds of treatments for pain and inflammation. Quartet Medicine, which officially launched a year ago with $17 million in Series A funding from Atlas, Novartis Venture Funds, Pfizer Venture Investment and Partners Innovation Fund, has closed that round at $23.25 million. The extra money comes from the Dallas venture firm, Remeditex, and what the company described as “two undisclosed Shanghai-based strategic investors.” Kevin Pojasek is president and acting CEO of Quartet Medicines, a new company developing… more Courtesy Atlas Remeditex CEO John Creecy has joined the board of Quartet, as well as Mark Corrigan , the former CEO of Zalicus , a Cambridge-based company which had been developing a type of drug for chronic pain known as calcium channel modulators. Two years ago, that company’s lead drug failed to show it was better than a placebo in a mid-stage trial, and last year Zalicus merged with a Boston drug company called Epirus Biopharmaceuticals (Nasdaq: EPRS) to focus on making generic versions of biologic drugs. Corrigan serves as chairman of the board of Epirus. Quartet is hoping to avoid the fate of drugs at Zalicus and several others in the field of pain management, which are difficult to prove effective in clinical trials. When I spoke to Quartet’s acting CEO and co-founder Kevin Pojasek a year ago, he explained that the company is targeting a chemical in the body called tetrahydrobiopterin (or BH4), a so-called cofactor which helps certain enzymes to work. Levels of BH4 are tied to pain and inflammation, and Quartets intends to use that as a biomarker to tell how effective its drugs are rather than relying only on the patient’s own subjective reporting. “In closing this financing we deepened our investor base and added the capital required to achieve both our near-term development candidate selection milestone as well as advance our first program through early clinical testing,” said Pojasek in a statement today. The company is located at the Atlas headquarters at 400 Technology Square in Kendall Square. Bizspace Spotlight

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Zalicus

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Zalicus is included in 3 Expert Collections, including Pharma Startups.

P

Pharma Startups

11,639 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

C

Cancer Therapeutics

1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

N

Neuroscience

2,144 items

Companies developing products that monitor, analyze, protect, or otherwise influence the structure/function of the nervous system.

Zalicus Patents

Zalicus has filed 9 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/27/2014

2/19/2019

Ion channels, Sodium channels, Analgesics, Ion channel toxins, Neurotoxins

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

2/27/2014

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

2/19/2019

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Ion channels, Sodium channels, Analgesics, Ion channel toxins, Neurotoxins

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.